Oncolytics Biotech Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on January 15, 2026. Oncolytics Biotech Inc. (ONCY), a company incorporated in Alberta, Canada, held a Special Meeting of Shareholders to vote on critical corporate restructuring proposals.
Key Financial Metrics
This filing is a current report regarding shareholder voting results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Shareholders approved three key proposals at the Special Meeting. A total of 17,596,480 shares (16.35% of outstanding shares) were present or represented by proxy.
- Proposal 1: Continuance from Alberta to British Columbia. Approved with 14,994,075 votes For and 2,602,405 votes Against.
- Proposal 2: Domestication from British Columbia to Nevada. Approved with 15,304,574 votes For and 2,291,905 votes Against. This moves the company's jurisdiction to the United States.
- Proposal 3: 2026 Incentive Award Plan. Approved with 13,508,657 votes For and 4,087,822 votes Against.
Outlook, Risks, and Management Commentary
Management announced the results via a press release filed as Exhibit 99.1. The domestication to Nevada is conditional upon the successful implementation of the continuance to British Columbia. The filing notes that this report is incorporated by reference into the Company's Registration Statement on Form F-3 (File No. 333-289819).
Investor Verification Checklist
- Verify the effective date of the domestication to the State of Nevada.
- Review the specific terms of the newly approved 2026 Incentive Award Plan.
- Confirm the impact of the jurisdictional change on existing shareholder rights and tax implications.
- Check the Form F-3 Registration Statement for details on how this restructuring affects future capital raising.